Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

19:25 EST 12th December 2018 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 669 from Net Resources International

Tuesday 11th December 2018

Ra Pharma reports positive top-line data from zilucoplan trial

Ra Pharmaceuticals has reported positive top-line results from a Phase II clinical trial assessing zilucoplan for the treatment of generalized...Read More... The post Ra Pharma reports positive top-line data from zilucoplan trial appeared first on Drug Development Technology.

BioLineRx starts triple combination arm of COMBAT/KEYNOTE-202 study

BioLineRx has commenced the triple combination arm of the Phase IIa COMBAT/KEYNOTE-202 trial of BL-8040 and keytruda (pembrolizumab) for the...Read More... The post BioLineRx starts triple combination arm of COMBAT/KEYNOTE-202 study appeared first on Drug Development Technology.

Aravive begins Phase Ib part of ovarian cancer drug trial

Aravive has commenced the Phase Ib portion of a clinical trial evaluating the combination of AVB-S6-500 with standard-of-care to treat...Read More... The post Aravive begins Phase Ib part of ovarian cancer drug trial appeared first on Drug Development Technology.

Monday 10th December 2018

Axovant reports negative topline data from nelotanserin trial

Axovant Sciences has reported negative topline results from a Phase II clinical trial of nelotanserin for the treatment of REM...Read More... The post Axovant reports negative topline data from nelotanserin trial appeared first on Drug Development Technology.

Voyager doses first patient in Phase II trial of VY-AADC

Voyager Therapeutics has dosed the first patient in the Phase II RESTORE-1 trial assessing the safety and efficacy of VY-AADC...Read More... The post Voyager doses first patient in Phase II trial of VY-AADC appeared first on Drug Development Technology.

Innovus Pharma enrols first subject in musclin trial

Innovus Pharmaceuticals has enrolled the first subject in a clinical trial designed to assess the effect and tolerance of musclin...Read More... The post Innovus Pharma enrols first subject in musclin trial appeared first on Drug Development Technology.

Sunday 9th December 2018

Generon reports positive data from breast cancer drug trial

Generon BioMed has reported positive results from a Phase III trial of F-627 for the treatment of women with breast...Read More... The post Generon reports positive data from breast cancer drug trial appeared first on Drug Development Technology.

Bio-Thera Solutions starts dosing in Phase I BAT4306F trial

Bio-Thera Solutions has started dosing patients in a Phase I clinical trial of BAT4306F to treat relapsed / refractory CD20-positive...Read More... The post Bio-Thera Solutions starts dosing in Phase I BAT4306F trial appeared first on Drug Development Technology.

Novartis reports new positive data from MONALEESA trials

Novartis has reported positive results from three pivotal Phase III MONALEESA trials evaluating kisqali (ribociclib) plus endocrine therapy in combination...Read More... The post Novartis reports new positive data from MONALEESA trials appeared first on Drug Development Technology.

Thursday 6th December 2018

Deals this week: Argenx, SmartZyme BioPharma, Viracta Therapeutics

Argenx will develop and license its cancer drug candidate cusatuzumab (ARGX-110) after partnering with Janssen Pharmaceutical’s affiliate company Cilag International. The two...Read More... The post Deals this week: Argenx, SmartZyme BioPharma, Viracta Therapeutics appeared first on Drug Development Technology.

Cytokinetics doses first subject in Phase I CK-274 trial

Cytokinetics has dosed the first subject in a Phase I trial evaluating the safety and tolerability of CK-3773274 (CK-274) to...Read More... The post Cytokinetics doses first subject in Phase I CK-274 trial appeared first on Drug Development Technology.

Centrexion completes enrolment in Phase III CNTX-4975 trial

Centrexion Therapeutics has completed patient enrolment ahead of schedule in the Phase III VICTORY-1 trial assessing the safety and efficacy...Read More... The post Centrexion completes enrolment in Phase III CNTX-4975 trial appeared first on Drug Development Technology.

Wednesday 5th December 2018

Exelixis and Ipsen start COSMIC-312 trial for advanced HCC

Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib...Read More... The post Exelixis and Ipsen start COSMIC-312 trial for advanced HCC appeared first on Drug Development Technology.

Daiichi Sankyo reports positive results from Phase I/II U3-1402 trial

Daiichi Sankyo has reported new positive efficacy and safety results from its ongoing Phase I/II study of U3-1402 in heavily...Read More... The post Daiichi Sankyo reports positive results from Phase I/II U3-1402 trial appeared first on Drug Development Technology.

Alkahest doses first patient in Phase II Parkinson’s drug trial

Alkahest has dosed the first subject in a Phase II clinical trial of GRF6021 to treat Parkinson’s disease associated with...Read More... The post Alkahest doses first patient in Phase II Parkinson’s drug trial appeared first on Drug Development Technology.

Tuesday 4th December 2018

ProQR receives FDA approval for Phase I/II QR-421a trial

ProQR Therapeutics has received approval from the US Food and Drug Administration (FDA) to begin the Phase I/II STELLAR trial...Read More... The post ProQR receives FDA approval for Phase I/II QR-421a trial appeared first on Drug Development Technology.

Seattle Genetics and Takeda report positive data from ECHELON-2 trial

Seattle Genetics and Takeda have reported positive topline results from the Phase II ECHELON-2 trial investigating adcetris (brentuximab vedotin) as...Read More... The post Seattle Genetics and Takeda report positive data from ECHELON-2 trial appeared first on Drug Development Technology.

Grail to begin trial of blood test for early cancer detection

Grail is set to start a new trial next year to assess the ability of an investigational blood test to...Read More... The post Grail to begin trial of blood test for early cancer detection appeared first on Drug Development Technology.

Monday 3rd December 2018

Biohaven reports positive topline results from zydis study

Biohaven Pharmaceutical has reported positive topline results from the Phase III BHV3000-303 or Study 303 clinical trial of zydis. The...Read More... The post Biohaven reports positive topline results from zydis study appeared first on Drug Development Technology.

Novartis starts Phase III trials of ligelizumab for urticaria

Novartis has commenced a pair of Phase III trials to evaluate the efficacy and safety of ligelizumab (QGE031) for the...Read More... The post Novartis starts Phase III trials of ligelizumab for urticaria appeared first on Drug Development Technology.

Janssen reports positive iLLUMINATE trial results

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported positive results from the iLLUMINATE (PCYC-1130) trial. iLLUMINATE is a...Read More... The post Janssen reports positive iLLUMINATE trial results appeared first on Drug Development Technology.

Sunday 2nd December 2018

Pfizer reports positive 26-week REFLECTIONS B328-06 study results

Pfizer has reported positive 26-week data from the ongoing Phase III REFLECTIONS B328-06 trial evaluating the safety and efficacy of...Read More... The post Pfizer reports positive 26-week REFLECTIONS B328-06 study results appeared first on Drug Development Technology.

Regeneron reports positive data from Phase I REGN1979 trial

Regeneron Pharmaceuticals has reported positive results from a Phase I trial evaluating the safety, tolerability and efficacy of REGN1979 to...Read More... The post Regeneron reports positive data from Phase I REGN1979 trial appeared first on Drug Development Technology.

Principia reports positive results from pemphigus drug trial

Principia Biopharma has reported positive top-line results from a Phase II trial of PRN1008 to treat patients with pemphigus vulgaris...Read More... The post Principia reports positive results from pemphigus drug trial appeared first on Drug Development Technology.

Thursday 29th November 2018

Deals this week: Nuformix, Fluidic Analytics, F2G Biotech

Nuformix has expanded its agreement with Newsummit Biopharma (NSB) for the licensing and commercialisation of cancer drug NXP001. Nuformix will...Read More... The post Deals this week: Nuformix, Fluidic Analytics, F2G Biotech appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks